Roche $ 5.3 billion contract for Zealand Pharma Strike obesity

Swiss drug giant Roche On Wednesday that the Danish biotech has hit up to 5.3 billion dollars to develop biotech development Zealand PharmaObesity candidate candidate, the two companies wanted to compete as a result of a loss of weight loss.

The deal will see the joint development and combination of the two companies Petrelintide, Zealand Pharra amillin analogue Like a connected therapy, as well as the Roche’s lead innest innest connection with a fixed dose with CT-388.

According to the agreement, Zealand Pharma, $ 1.65 billion, $ 1.65 billion, the potential of the potential capacity of the potential capacity of the potential capacity of the potential of the potential of the potential of the potential, Faz-3 tests and sales, Roche said.

Zealand Pharma shares jumped 29% shortly after the announcement and added 27% to 11:25, while Roche added 5.4%.

Stockings of obesity medicinal giant Novo NordiskMeanwhile, 3.9% slipped at a meeting on Wednesday Eli lilli 1.5% decreased in trade before the market.

Zealand Pharma CEO and President Adam Steensberg told CNBC that the contract showed a strong commitment to the future of two companies in the future. “

Steensberg said the company received a “high interest rate” because last year’s partnership discussions. However, Roche noted that he was “most desirable” with reference to the Swiss company Previous developments Getting the GLP-1 manufacturer in the drug market, including the manufacturer of carmot therapeutics.

“Roche convinced us that they were deprived of leadership in this therapeutic space,” Steensberg told CNBC via CNBC via video call on Wednesday.

Added that the firm’s market leaders are associated with Novo or Lilly, GLP-1 obesity drug franchise, respectively, respectively

Bank of America Securities Celebrated the Roche Partnership on Wednesday, GLP-1S and a “best job scenario”, taking into account the work between the mechanisms.

The expected bargaining, Roche and Zelandan in the United States and Europe in the second quarter traded with two shareholders and losses based on 50/50 in the US and Europe. Roche will acquire exclusive trade rights in the rest of the world.

Zealand Pharma has long pointed to amillin analogues “The next generation” weight loss treatment. They are working by imitating a hormone that combines with insulin in the pancreas to increase grumpy. It differs from GLP-1 agonists that imitate the hormones that imitate the hormones produced in the gut to suppress the appetite and adjust blood sugar.

“Unlike GLP-1S, which makes people without appetite, Petrelintide can help people feel faster than himself,” Steensberg said.